332 | A MULTI‐CENTER PROSPECTIVE PHASE II CLINICAL TRIAL OF THE MEDZ‐R REGIMEN FOR THE TREATMENT OF NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Ähnliche Einträge

• 713 | CHEMOTHERAPY‐FREE THERAPY WITH RITUXIMAB, LENALIDOMIDE, AND POSELTINIB IN RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTI‐CENTER, PHASE II STUDY
  von: D. H. Kim, et al.
  Veröffentlicht: (2025)
• 165 | LINPERLISIB PLUS CHOP FOR NEWLY DIAGNOSED PERIPHERAL T‐CELL LYMPHOMA: A SINGLE‐ARM, OPEN‐LABLE, MULTI‐CENTER PHASE IB/II STUDY (LINCH TRIAL)
  von: Q. Cai, et al.
  Veröffentlicht: (2025)
• 334 | A PHASE I/II STUDY OF ORELABRUTINIB COMBINED WITH ANTI‐PD‐1 ANTIBODY AND FOTEMUSTINE FOR PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
  von: W. Zhao, et al.
  Veröffentlicht: (2025)
• 751 | GOLIDOCITINIB COMBINED WITH CHOP IN NEWLY‐DIAGNOSED PERIPHERAL T‐CELL LYMPHOMA: PRELIMINARY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL
  von: W. Zhang, et al.
  Veröffentlicht: (2025)
• 307 | IMPACT OF CELL OF ORIGIN, GENE REARRANGEMENTS, FRONTLINE TREATMENT ON INCIDENCE OF CENTRAL NERVOUS SYSTEM LYMPHOMA RELAPSE IN NEWLY DIAGNOSED LARGE B‐CELL LYMPHOMA
  von: A. S. Falade, et al.
  Veröffentlicht: (2025)